953 related articles for article (PubMed ID: 8640159)
21. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
22. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
25. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
[TBL] [Abstract][Full Text] [Related]
26. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
27. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
28. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.
Haas R; Moos M; Karcher A; Möhle R; Witt B; Goldschmidt H; Frühauf S; Flentje M; Wannenmacher M; Hunstein W
J Clin Oncol; 1994 Aug; 12(8):1685-92. PubMed ID: 7518860
[TBL] [Abstract][Full Text] [Related]
29. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
30. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.
Haas R; Brittinger G; Meusers P; Murea S; Goldschmidt H; Wannenmacher M; Hunstein W
Leukemia; 1996 Dec; 10(12):1975-9. PubMed ID: 8946940
[TBL] [Abstract][Full Text] [Related]
31. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
[TBL] [Abstract][Full Text] [Related]
32. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
33. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
34. Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors.
Haas R; Hohaus S; Ehrhardt R; Goldschmidt H; Hunstein W
Bone Marrow Transplant; 1993; 11 Suppl 2():30-5. PubMed ID: 8101459
[TBL] [Abstract][Full Text] [Related]
35. High-dose cytotoxic therapy with autologous bone marrow or peripheral blood progenitor cell transplantation in malignant lymphomas.
Cucuianu A; D'Hondt L; Collignon J; Verhulst D; Deprijck B; Chatelain C; Doyen C; Bosly A
Rom J Intern Med; 1995; 33(3-4):211-25. PubMed ID: 8646194
[TBL] [Abstract][Full Text] [Related]
36. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
[TBL] [Abstract][Full Text] [Related]
37. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
38. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution.
Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A
Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431
[TBL] [Abstract][Full Text] [Related]
40. Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Doorduijn JK; Spruit P; van Der Holt B; van't Veer M; Budel L; Löwenberg B; Sonneveld P
Haematologica; 2000 Aug; 85(8):814-9. PubMed ID: 10942927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
